[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Longwood Biopharmaceuticals Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100635729","phase-2-evaluation-of-the-efficacy-and-safety-of-lw402-tablets-in-patients-with-non-segmental-vitiligo-100635729",false,"NCT07556471","Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive), with no restriction on gender;\n* Clinically diagnosed with non-segmental vitiligo at screening;\n* At the screening visit and baseline visit, the Facial Vitiligo Area Scoring Index (F-VASI) is ≥ 0.5 and the Total Vitiligo Area Scoring Index (T-VASI) is ≥ 3;\n* At the screening visit and baseline visit, the disease is in the progressive stage or stable stage;\n\nExclusion Criteria:\n\n* Individuals with a known allergy to Janus kinase inhibitors；\n* Segmental vitiligo, mixed vitiligo, or undetermined vitiligo；\n* White hair is present in more than 33% of facial skin lesions due to vitiligo, or in more than 33% of total skin lesions due to vitiligo;\n* Skin lesions due to vitiligo are restricted to hairless areas, or hairless regions account for ≥30% of the lesion sites (e.g., lips, palms, fingers, labia);\n* Individuals with other active hypopigmentary conditions during the screening period (including but not limited to Vogt-Koyanagi-Harada syndrome, hypopigmentation associated with malignant tumors \\[melanoma and mycosis fungoides\\], post-inflammatory hypopigmentation, pityriasis alba \\[a mild manifestation of atopic dermatitis\\], senile leukoderma \\[age-related depigmentation\\], chemical\u002Fdrug-induced leukoderma, ataxia-telangiectasia, tuberous sclerosis complex, melasma, and congenital hypopigmentary disorders \\[including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, hereditary symmetrical dyschromatosis, xeroderma pigmentosum, and nevus depigmentosus\\]) are excluded. Note: Coexisting halo nevus (also referred to as Sutton nevus) is permitted;","ALL","18 Years","75 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo.\n\nDrawing on the prior\u002Fpreclinical data of LW402 tablets, this clinical trial will incorporate three dose groups: 50 mg twice daily (BID), 100 mg BID, and 150 mg BID. The trial will be structured into a screening period (maximum 5 weeks), a treatment period (52 weeks, encompassing a 24-week main trial phase and a 28-week extension phase), and a safety follow-up period (4 weeks). The maximum duration of participation in this study will be 61 weeks.\n\nFollowing the completion of 24-week data collection for all trial participants, unblinding will be performed in accordance with the pre-specified procedure. Subsequently, based on the unblinded data results, regulatory communication will be conducted with the Center for Drug Evaluation (CDE) regarding the initiation of the Phase III confirmatory clinical trial. Participants who have undergone unblinding will continue to attend scheduled study visits to complete the trial.",[27],"Non-Segmental Vitiligo (NSV)",[29],"LW402 Tablets,Phase II,Non-segmental Vitiligo","NOT_YET_RECRUITING","2026-04-28",{"date":33,"type":34},"2026-04-29","ACTUAL",{"date":36,"type":21},"2026-05-31",{"date":38,"type":21},"2028-12-31",{"name":40,"class":41},"Shanghai Longwood Biopharmaceuticals Co., Ltd.","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":63},"100621460","phase-3-evaluation-of-the-efficacy-and-safety-of-oral-lw402-tablets-for-the-treatment-of-patients-with-moderate-to-severe-atopic-dermatitis-100621460","NCT07370909","Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis","A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.","Inclusion Criteria:\n\n* Subjects voluntarily provided informed consent and agreed to participate in the study.\n* Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signing the informed consent form).\n* At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopic dermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior to screening.\n* At screening and baseline visits, subjects were required to have moderate-to-severe atopic dermatitis (AD) with all three of the following criteria satisfied:\n\n  * Total AD lesion area ≥ 10% of body surface area (BSA)\n  * Investigator's Global Assessment (IGA) score ≥ 3\n  * Eczema Area and Severity Index (EASI) score ≥ 16\n\nExclusion Criteria:\n\n* Subjects with a documented history of hypersensitivity to Janus kinase (JAK) inhibitors.\n* Subjects with current or a history of autoimmune diseases other than atopic dermatitis (AD) (e.g., systemic lupus erythematosus \\[SLE\\], inflammatory bowel disease \\[IBD\\], Felty's syndrome, scleroderma, inflammatory myopathy, other connective tissue diseases, overlap syndrome) or other skin conditions that may interfere with AD assessment (e.g., contact dermatitis, psoriasis).",{"count":50,"type":21},480,[52],"PHASE3","This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.",[55],"Moderate to Severe Atopic Dermatitis","2026-01-27",{"date":58,"type":34},"2026-01-29",{"date":60,"type":21},"2026-01-30",{"date":38,"type":21},{"name":40,"class":41},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100606747","phase-1-study-of-lw231-in-participants-with-chronic-hepatitis-b-100606747","NCT07179575","Study of LW231 in Participants With Chronic Hepatitis B","Phase Ib\u002FII Study of LW231 in Patients With Chronic Hepatitis B: Evaluation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy With Multiple-Dose, Dose-Escalation, and Combination With Nucleos(t)Ide Analogs (NUC)","Inclusion Criteria:\n\n* Part 1: treatment-naïve and currently not treated subjects: LLOQ\\\u003CHBV DNA≤20000 IU\u002Fml; 100 IU\u002FmL\\\u003CHBsAg\\\u003C10000 IU\u002Fml\n* Part 2: HBV DNA\\\u003CLLOQ or \\\u003C 20 IU\u002FmL at screening; 100 IU\u002FmL\\\u003CHBsAg\\\u003C3000 IU\u002FmL\n\nExclusion Criteria:\n\n* Co-infection with hepatitis A, C, D, E or HIV or any evidence of clinically significant liver disease of non-HBV etiology.\n* History or current evidence of cirrhosis.\n* ALT or AST\\>3×ULN; TBil\\>1.3×ULN or DBil\\>1.3×ULN; INR\\>1.3×ULN","60 Years",{"count":73,"type":21},270,[75,24],"PHASE1","This is a Phase Ib\u002FII, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B virus (HBV) infection. The trial will include multiple-dose regimens of LW231 and assess LW231 in combination with NUCs.",[78],"Chronic HBV Infection","RECRUITING","2025-09-28",{"date":82,"type":34},"2025-10-02",{"date":84,"type":21},"2025-10",{"date":86,"type":21},"2027-11",{"name":40,"class":41},2,""]